DUBLIN, June 23, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Key Pharma News Issue 53" report to their offering.
2015 FDA novel cancer drug approvals highlighted high innovation levels, but it was just an indication of the potential yet to be unlocked within the field. FDA novel approval rates will increase considerably with the purging of pipelines containing high numbers of targeted cancer agents. Stratification of diseases through better genomic understanding and diagnostic techniques will corroborate the FDA's support for expedited review times for promising novel agents, and we should see record approval times persist. Orphan drug parameters may face changes as the healthcare system ultimately struggles to deal with the deluge of eligible drugs.
Key Topics Covered:
1. Agreements
- Academia To Benefit From Increasing Value Placed On Innovation
2. Corporate Activity
- Lupin Completes Gavis And Novel Acquisitions
- Astellas/MTP Team Up To Share Compound Drug Libraries
3. Product News
- FDA Approves Elusys' Anthim For Anthrax
- Increasingly Negative Opioid Opinion Will Drive Down Consumption
- IGBA Special 301 Submission Highlights Need For Common Ground
- Apotex Launches Mometasone Nasal Spray
- Eli Lilly Gains FDA Taltz Approval For Moderate-To-Severe Plaque Psoriasis
- FDA's Opioid Policies Will Drive The Market Towards Alternatives
4. R&D
- Praluent Phase III Study Meets Primary Endpoint In HeFH
- Disease Interception Represents Paradigm Shift For Healthcare
For more information visit http://www.researchandmarkets.com/research/6cl88k/key_pharma_news
Media Contact:
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article